Digest Network Come funziona
Network
/
Società
Al
Non verificato

Alnylam Pharmaceuticals, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteWeb e Social Network

54 comunicati stampa

Guarda tutti i comunicati
03/12/2025
Mercato del lavoro
Biotecnologia
Farmaceutica
Salute
Alnylam Pharmaceuticals Announces Changes to Board of Directors
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
08/11/2025
Scienza
Cardiologia
Biotecnologia
Farmaceutica
Salute
Igiene alimentare
Medicina - Varie
Eventi
Analisi di mercato
New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
04/11/2025
Web e Social Network
Eventi
Finanza
Biotecnologia
Farmaceutica
Salute
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
30/10/2025
Web e Social Network
Telefonia e Varie
Mercato azionario
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Cardiologia
Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
16/10/2025
Biotecnologia
Farmaceutica
Salute
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
01/10/2025
Biotecnologia
Farmaceutica
Salute
Cardiologia
Industria
Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
29/09/2025
Biotecnologia
Farmaceutica
Salute
Cardiologia
Eventi
Industria
New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
28/09/2025
Biotecnologia
Farmaceutica
Salute
Cardiologia
Eventi
Industria
New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
10/09/2025
Biotecnologia
Farmaceutica
Salute
Titoli e azioni
Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
08/09/2025
Biotecnologia
Farmaceutica
Salute
Titoli e azioni
Alnylam Announces Proposed Offering of $500 Million Convertible Senior Notes
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0